BZLF1 controlled by family repeat domain induces lytic cytotoxicity in Epstein-Barr virus-positive tumor cells

被引:0
作者
Wang, H
Zhao, Y
Zeng, L
Tang, M
El-Deeb, A
Li, JJ
Cao, Y
机构
[1] City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Oncol, Duarte, CA 91010 USA
[2] Cent S Univ, Xiangya Sch Med, Canc Res Inst, Changsha 410078, Hunan, Peoples R China
关键词
gene therapy; Epstein-Barr virus; BZLF1; lytic replication;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: BZLF1, an EBV (Epstein-Barr virus) immediate early gene, is required for EBV lytic replication that causes the death of host cells. EBNA1, the product of EBV latent gene, binds to the family repeats (FR) of the origin of replication (Orip) regulating EBV replication. Materials and Methods: A vector pFR-Z (BZLF1 controlled by FR domain of EBV) was constructed and transfected into EBV-positive 5-8F and-negative HNE3 nasopharyngeal carcinoma cells and BZLF1-induced cytotoxicity was tested. Results: EBNA1 expression was detected in 5-8F but not HNE3 cells and, in agreement, pFR controlled luciferase expression was activated in 5-8F cells but inhibited in HNE3 cells. Gardella gel assay demonstrated that pFR-Z effectively induced EBV lytic replication in 5-8F but not HNE3 cells. The lytic cytotoxicity was confirmed by a diminished cell survival and the induction of lytic proteins EA-D and gp125. The cytotoxicity was also strikingly enhanced by addition of GCV (gancyclovir) that kill cells with lytic form EBV Conclusion: pFR-Z is a specific gene therapy vehicle for EBV-positive carcinomas.
引用
收藏
页码:67 / 74
页数:8
相关论文
共 37 条
  • [1] ALYAR A, 1998, EMBO J, V17, P6394
  • [2] Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma
    Ambinder, RF
    Robertson, KD
    Moore, SM
    Yang, J
    [J]. SEMINARS IN CANCER BIOLOGY, 1996, 7 (04) : 217 - 226
  • [3] Cazaux C, 1998, CANCER GENE THER, V5, P83
  • [4] No significant association of Epstein-Barr virus infection with invasive breast carcinoma
    Chu, PGG
    Chang, KL
    Chen, YY
    Chen, WG
    Weiss, LM
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (02) : 571 - 578
  • [5] CONNERS TA, 2000, GENE THER, V2, P702
  • [6] The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators
    Feederle, R
    Kost, M
    Baumann, M
    Janz, A
    Drouet, E
    Hammerschmidt, W
    Delecluse, HJ
    [J]. EMBO JOURNAL, 2000, 19 (12) : 3080 - 3089
  • [7] Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors
    Feng, WH
    Westphal, E
    Mauser, A
    Raab-Traub, N
    Gulley, ML
    Busson, P
    Kenney, SC
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (21) : 10951 - 10959
  • [8] TRANS-ACTING REQUIREMENTS FOR REPLICATION OF EPSTEIN-BARR-VIRUS ORI-LYT
    FIXMAN, ED
    HAYWARD, GS
    HAYWARD, SD
    [J]. JOURNAL OF VIROLOGY, 1992, 66 (08) : 5030 - 5039
  • [9] FREEMAN SM, 1993, CANCER RES, V53, P5274
  • [10] THE EPSTEIN-BARR VIRUS ORIGIN OF PLASMID REPLICATION, ORIP, CONTAINS BOTH THE INITIATION AND TERMINATION SITES OF DNA-REPLICATION
    GAHN, TA
    SCHILDKRAUT, CL
    [J]. CELL, 1989, 58 (03) : 527 - 535